Vaxcyte (PCVX) Income from Continuing Operations (2019 - 2026)
Vaxcyte (PCVX) posted quarterly Income from Continuing Operations of 322947000.0 for Q1 2026, down 113.95% year-over-year from 2314307841.9 in Q1 2025, and up 14.61% quarter-over-quarter from 378183000.0 in Q4 2025.
Vaxcyte (PCVX) Income from Continuing Operations (2019 - 2026) Analysis & Trends
Vaxcyte (PCVX) has reported Income from Continuing Operations for 8 consecutive years, with 322947000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Income from Continuing Operations fell 113.95% year-over-year to 322947000.0; the TTM figure through Mar 2026 stood at 1348394000.0 (down 160.47% YoY), while the FY2025 annual figure was 1449270000.0, down 60.03% from the prior year.
- Income from Continuing Operations rose to 322947000.0 in Q1 2026 per PCVX's latest filing, from 378183000.0 in the prior quarter.
- Across five years, Income from Continuing Operations topped out at 79940000.0 in Q4 2022 and bottomed at 455931000.0 in Q1 2024.
- Historically, Income from Continuing Operations has averaged 224236000.0 across 5 years, with a median of 179108000.0 in 2023.
- Annual changes were most pronounced in 2022 — Income from Continuing Operations sank 380.33% — and 2025, when it surged 66.89%.
- Vaxcyte's Income from Continuing Operations stood at 79940000.0 in 2022, then sank by 124.05% to 179108000.0 in 2023, then surged by 34.51% to 117305000.0 in 2024, then sank by 222.39% to 378183000.0 in 2025, then advanced by 14.61% to 322947000.0 in 2026.
- Business Quant data shows PCVX's Income from Continuing Operations at 322947000.0 in Q1 2026, 378183000.0 in Q4 2025, and 331148000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 482.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -644.37 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 237.01 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -3,096.02 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 81.49 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 164.49 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -13.27 Mn |
| 10 | Vaxcyte | 8.41 Bn | 8.41 Bn | - | -477.96 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -477.96 Mn |
| Mar 31, 2026 | -322.95 Mn |
| Dec 31, 2025 | -378.18 Mn |
| Sep 30, 2025 | -331.15 Mn |
| Jun 30, 2025 | -316.12 Mn |
| Mar 31, 2025 | -150.94 Mn |
| Dec 31, 2024 | -117.31 Mn |
| Sep 30, 2024 | -115.48 Mn |
| Jun 30, 2024 | -133.95 Mn |
| Mar 31, 2024 | -455.93 Mn |
| Dec 31, 2023 | -179.11 Mn |
| Sep 30, 2023 | -343.44 Mn |
| Jun 30, 2023 | -316.10 Mn |
| Mar 31, 2023 | -207.79 Mn |
| Dec 31, 2022 | -79.94 Mn |
| Sep 30, 2022 | -131.53 Mn |
| Jun 30, 2022 | -113.54 Mn |
| Mar 31, 2022 | -118.57 Mn |
| Dec 31, 2021 | -29.75 Mn |
| Sep 30, 2021 | -120.32 Mn |